| Name | Title | Contact Details |
|---|
RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force of approximately 40 sales representatives promoting two speciality gastrointestinal products in select U.S. territories. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise. '
Nystrom & Associates Here at Nystrom & Associates, we know that you want to feel confident and excited about life. Were here to help!
Particle Dynamics is a company that provides innovative technologies, quality ingredients, and custom processing capabilities that deliver solutions for the pharmaceutical, consumer health, OTC, and nutraceutical markets.
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Companys principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through ...
Biosynexus understands that bringing a new pharmaceutical product to market is a complicated process that involves not only having strong research and development capabilities, but also having deep clinical development, manufacturing and marketing